Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. This burden will increase further as the population ages and the degree of polypharmacy increases. Knowledge about DDIs comes from many sources, with rigorous population-based studies of clinical outcomes providing the most clinically useful information. Because very few population DDI studies have been performed, there is profound disagreement among the DDI compendia about which drug pairs cause clinically important DDIs. Further, uncertainty about which potential DDIs are clinically important has hampered efforts to mitigate the effects of DDIs, such as computerized decision support. Population studies of the clinical effects of DDIs are therefore badly needed, and should be integrated with research on the biological basis of DDIs. In this renewal application, we propose to extend our approach to population DDI studies in two important and innovative ways: 1) by actively and explicitly incorporating mechanistic considerations;and 2) by implementing a sequential approach of initially identifying and quantifying risk, then, where warranted based on this step, characterizing important DDIs further, with the goal of providing the basis for future efforts to mitigate risk. Based on an extensive and structured consultative process to identify research foci, we propose to conduct a series of population DDI studies using a large 5-state Medicaid/Medicare dataset. These studies will examine hypothesized interactions involving lipid lowering drugs, anti-clotting drugs, and oral anti-diabetic drugs, three drug classes with enormous relevance for older adults, and with high potential for causing clinically important DDIs. Thus, we will study potential DDIs of great clinical and public health importance, especially to older adults, and in the process develop data that will help elucidate the mechanisms of these potential DDIs.
Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. However, little is known about the clinical importance of most potential DDIs. We will conduct large population studies of the clinical importance of potential DDIs affecting lipid lowering, anti-clotting, and anti-diabetic therapies, addressing potential DDIs of great clinical and public health importance.
|Leonard, Charles E; Han, Xu; Bilker, Warren B et al. (2016) Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Res Clin Pract 115:60-7|
|Ji, Xinyao; Small, Dylan S; Leonard, Charles E et al. (2016) The Trend-in-Trend Research Design for Causal Inference. Epidemiology :|
|Hennessy, S; Leonard, C E; Gagne, J J et al. (2016) Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions. Clin Pharmacol Ther 99:92-100|
|Leonard, C E; Bilker, W B; Brensinger, C M et al. (2016) Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. Clin Pharmacol Ther 99:538-47|
|Flory, James; Haynes, Kevin; Leonard, Charles E et al. (2015) Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes. Br J Clin Pharmacol 79:330-6|
|Leonard, Charles E; Bilker, Warren B; Brensinger, Colleen M et al. (2015) Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke 46:722-31|
|Ogdie, Alexis; Yu, YiDing; Haynes, Kevin et al. (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74:326-32|
|Hennessy, Sean; Kurichi, Jibby E; Pan, Qiang et al. (2015) Disability Stage is an Independent Risk Factor for Mortality in Medicare Beneficiaries Aged 65 Years and Older. PM R 7:1215-25|
|Hennessy, Sean; Strom, Brian L (2015) Improving postapproval drug safety surveillance: getting better information sooner. Annu Rev Pharmacol Toxicol 55:75-87|
|Byrne, D D; Newcomb, C W; Carbonari, D M et al. (2015) Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. J Viral Hepat 22:936-47|
Showing the most recent 10 out of 28 publications